The clinically used iron chelator deferasirox is an inhibitor of epigenetic jumonjiC domain-containing histone demethylases

The clinically used iron chelator deferasirox is an inhibitor of epigenetic jumonjiC domain-containing histone demethylases

Fe(II)- and 2-oxoglutarate (2OG)-dependent JumonjiC domain-containing histone demethylases (JmjC KDMs) are epigenetic eraser enzymes involved in the regulation of gene expression and are emerging drug targets in oncology. We screened a set of clinically used iron chelators and report that they poten...

Descrizione completa

Dettagli Bibliografici
Autori principali: Roatsch, M, Hoffmann, I, Abboud, MI, Hancock, RL, Tarhonskaya, H, Hsu, K-F, Wilkins, SE, Yeh, T-L, Lippl, K, Serrer, K, Moneke, I, Ahrens, TD, Robaa, D, Wenzler, S, Barthes, NPF, Franz, H, Sippl, W, Lassmann, S, Diederichs, S, Schleicher, E, Schofield, CJ, Kawamura, A, Schüle, R, Jung, M
Natura: Journal article
Lingua:English
Pubblicazione: ACS Publications 2019

Documenti analoghi